Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma

BAY 1143572 is a highly selective inhibitor of cyclin-dependent kinase 9/positive transcription elongation factor b. It has entered phase I clinical studies. Here, we have assessed the utility of BAY 1143572 for treating natural killer (NK) cell leukemias/lymphomas that have a poor prognosis, namely...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Haematologica
Egile Nagusiak: Kinoshita, Shiori, Ishida, Takashi, Ito, Asahi, Narita, Tomoko, Masaki, Ayako, Suzuki, Susumu, Yoshida, Takashi, Ri, Masaki, Kusumoto, Shigeru, Komatsu, Hirokazu, Shimizu, Norio, Inagaki, Hiroshi, Kuroda, Taruho, Scholz, Arne, Ueda, Ryuzo, Sanda, Takaomi, Iida, Shinsuke
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6269314/
https://ncbi.nlm.nih.gov/pubmed/30076184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.191395
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak